Trust Co. of Vermont lowered its position in shares of Metlife Inc (NYSE:MET) by 22.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,353 shares of the financial services provider’s stock after selling 970 shares during the period. Trust Co. of Vermont’s holdings in Metlife were worth $171,000 as of its most recent SEC filing.
Other large investors have also recently modified their holdings of the company. BlackRock Inc. lifted its position in Metlife by 1.9% during the second quarter. BlackRock Inc. now owns 72,819,515 shares of the financial services provider’s stock valued at $3,616,945,000 after purchasing an additional 1,385,433 shares during the last quarter. Valeo Financial Advisors LLC lifted its position in Metlife by 26.5% during the third quarter. Valeo Financial Advisors LLC now owns 5,172 shares of the financial services provider’s stock valued at $244,000 after purchasing an additional 1,084 shares during the last quarter. SeaCrest Wealth Management LLC lifted its position in Metlife by 16.7% during the third quarter. SeaCrest Wealth Management LLC now owns 10,058 shares of the financial services provider’s stock valued at $474,000 after purchasing an additional 1,441 shares during the last quarter. DNB Asset Management AS lifted its position in Metlife by 3.2% during the third quarter. DNB Asset Management AS now owns 194,027 shares of the financial services provider’s stock valued at $9,150,000 after purchasing an additional 6,015 shares during the last quarter. Finally, Sumitomo Mitsui DS Asset Management Company Ltd lifted its position in Metlife by 5.9% during the third quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 49,914 shares of the financial services provider’s stock valued at $2,353,000 after purchasing an additional 2,789 shares during the last quarter. 74.45% of the stock is owned by institutional investors.
Several brokerages have issued reports on MET. ValuEngine upgraded shares of Metlife from a “strong sell” rating to a “sell” rating in a research report on Saturday, December 21st. Morgan Stanley upgraded shares of Metlife from an “equal weight” rating to an “overweight” rating and lifted their target price for the company from $55.00 to $60.00 in a research report on Tuesday, January 7th. Zacks Investment Research upgraded shares of Metlife from a “sell” rating to a “hold” rating and set a $52.00 target price for the company in a research report on Monday, December 9th. Wells Fargo & Co reiterated a “buy” rating on shares of Metlife in a research report on Monday, January 6th. Finally, Credit Suisse Group dropped their target price on shares of Metlife from $63.00 to $60.00 and set an “outperform” rating for the company in a research report on Monday, February 3rd. Two analysts have rated the stock with a sell rating, five have given a hold rating and five have given a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $52.60.
Metlife (NYSE:MET) last announced its quarterly earnings data on Wednesday, February 5th. The financial services provider reported $1.98 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.40 by $0.58. The firm had revenue of $18.15 billion during the quarter, compared to analyst estimates of $16.82 billion. Metlife had a net margin of 8.39% and a return on equity of 9.14%. The business’s quarterly revenue was up 17.9% on a year-over-year basis. During the same period in the previous year, the business posted $1.35 EPS. Research analysts anticipate that Metlife Inc will post 6.1 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 13th. Stockholders of record on Tuesday, February 4th will be issued a $0.44 dividend. The ex-dividend date of this dividend is Monday, February 3rd. This represents a $1.76 dividend on an annualized basis and a dividend yield of 3.39%. Metlife’s payout ratio is 28.81%.
In other news, EVP Steven J. Goulart sold 14,200 shares of the business’s stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $51.60, for a total value of $732,720.00. Following the completion of the sale, the executive vice president now directly owns 127,130 shares in the company, valued at approximately $6,559,908. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 0.31% of the company’s stock.
Metlife Company Profile
MetLife, Inc engages in the insurance, annuities, employee benefits, and asset management businesses. It operates through five segments: U.S.; Asia; Latin America; Europe, the Middle East and Africa; and MetLife Holdings. The company offers life, dental, group short- and long-term disability, individual disability, accidental death and dismemberment, vision, and accident and health coverages, as well as prepaid legal plans; administrative services-only arrangements to employers; and stable value products, including general and separate account guaranteed interest contracts, and private floating rate funding agreements.
Featured Story: What is Liquidity?
Want to see what other hedge funds are holding MET? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Metlife Inc (NYSE:MET).
Receive News & Ratings for Metlife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Metlife and related companies with MarketBeat.com's FREE daily email newsletter.